Funding round
Xaira Therapeutics Growth
Reported as "Growth Equity"
Xaira Therapeutics, which works in AI-Driven drug discovery and development in South San Francisco, raised $1.00B in a Growth round announced on 23 Apr 2024, led by ARCH Venture Partners and Foresite Capital. 13 firms took part.
$1.00B
Amount raised
Not disclosed
Post-money valuation
13
Investors
2 leads
Valuation
What this round says about the price
Xaira Therapeutics did not disclose a valuation in this round. It is Xaira Therapeutics' first venture round on record, 1 year after it was founded in 2023. No later venture round is on record for Xaira Therapeutics.
Xaira Therapeutics' funding rounds
This is the only venture round on record for Xaira Therapeutics.
- Growth this round 23 Apr 2024, led by ARCH Venture Partners and Foresite Capital $1.00B
Investors
Who put money in
ARCH Venture Partners and Foresite Capital led the round with 11 other firms.
Lead investors
- ARCH Venture Partners backs 99 venture-backed companies new investor
- backs 39 venture-backed companies new investor
Also in the round
- backs 118 venture-backed companies new investor
- New Enterprise Associates backs 286 venture-backed companies new investor
- Sequoia Capital backs 589 venture-backed companies new investor
- Lux Capital backs 194 venture-backed companies new investor
- Lightspeed Venture Partners backs 454 venture-backed companies new investor
- Menlo Ventures backs 215 venture-backed companies new investor
- Two Sigma Ventures backs 60 venture-backed companies new investor
- Parker Institute for Cancer Immunotherapy new investor
- backs 13 venture-backed companies new investor
- backs 8 venture-backed companies new investor
- SV Angel backs 293 venture-backed companies new investor
Use of proceeds
What the money is for
According to the announcement, the money goes to product development.
- Product development
Comparable rounds
How it compares
36 Growth rounds in Biotechnology within a year either side disclosed an amount; the median was $51M, and this round was 20 times the median. The closest in time, other companies' Growth rounds in Biotechnology:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| Biotechnology | 21 May 2024 | $52M | not disclosed | Insight Partners and UCB Ventures |
| Biotechnology | 7 May 2024 | $50M | not disclosed | Flagship Pioneering |
| Biotechnology | 24 May 2024 | $35M | not disclosed | not named |
| Biotechnology | 21 Mar 2024 | $35M | not disclosed | Spark Capital |
| Biotechnology | 14 Mar 2024 | $32M | not disclosed | Pfizer Venture Investments and Sofinnova Partners |
| Biotechnology | 28 May 2024 | $27M | not disclosed | not named |
| Biotechnology | 29 Feb 2024 | $210M | not disclosed | Gilead Sciences |
| Biotechnology | 18 Jun 2024 | $190M | not disclosed | Forbion and Sofinnova Partners |
Sources
Where this comes from
Reported by 7 sources.
Questions
Frequently asked
How much did Xaira Therapeutics raise in its Growth round?
Xaira Therapeutics raised $1.00B in its Growth round, announced in Apr 2024.
Who led Xaira Therapeutics' Growth round?
ARCH Venture Partners and Foresite Capital led it, with F-Prime Capital, New Enterprise Associates, Sequoia Capital, Lux Capital and Lightspeed Venture Partners and 6 more.
What was Xaira Therapeutics' valuation at the Growth round?
It was not disclosed.
How does it compare with other Growth rounds in Biotechnology?
36 Growth rounds in Biotechnology within a year either side disclosed an amount; the median was $51M, and this round was 20 times the median.